Publication: Anticuerpos específicos de enfermedad celíaca: relación con otros pruebas diagnósticas e implicaciones clínicas
Loading...
Files
Official URL
Full text at PDC
Publication Date
2017-09-11
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
La Enfermedad Celíaca (EC) es una enteropatía autoinmune de carácter crónico, dependiente de gluten y que se acompaña de anticuerpos específicos en individuos predispuestos genéticamente. Los anticuerpos pueden estar dirigidos frente a la enzima transglutaminasa tisular tipo 2 (a-TG2 o anticuerpos frente a endomisio, EMA) o frente a péptidos deamidados de gliadina (a-PDG). Hace unos años se desarrolló un kit que combina la transglutaminasa tisular tipo 2 con péptidos específicos de gliadina (a-TG2-GL) y que por tanto puede detectar anticuerpos frente a TG2, frente a péptidos derivados del gluten y se ha descrito que también frente a neoepítopos que se generan tras el entrecruzamiento fisiológico de la TG2 con péptidos de gliadina. Respecto a la genética, la presencia de las combinaciones alélicas HLA-DQ2 (DQA1*05-DQB1*02) y/o HLA-DQ8 (DQA1*03-DQB1*03:02), son las consideradas de riesgo a desarrollar la enfermedad. La biopsia duodenal constituye un pilar importante en el diagnóstico, aunque las lesiones encontradas en la EC no son patognomónicas...
Celiac disease (CD) is a chronic autoimmune enteropathy which is developed after gluten-ingestion in genetically susceptible individuals and commonly appears accompanied by specific antibodies. These antibodies can be directed against type 2 transglutaminase enzyme (a-TG2 or endomysial antibodies, EMA) or deamidated gliadin peptides (a-DGP). Years ago, a different commercial kit which combine type 2 transglutaminase and specific gliadin peptides was developed (a-TG2-GL), which can detect antibodies against TG2, against gluten-derived peptides and it has been described that it also recognizes neoepitopes that are generated after the physiological crosslinking between TG2 and gliadin peptides. Regarding genetics, the HLA-DQ2 (DQA1*05 - DQB1*02) and/or HLA-DQ8 (DQA1*03 - DQB1*03:02) haplotypes are the ones considered to confer risk to develop the disease. Duodenal biopsy has an important diagnostic value, although the lesions found in CD are not pathognomonic...
Celiac disease (CD) is a chronic autoimmune enteropathy which is developed after gluten-ingestion in genetically susceptible individuals and commonly appears accompanied by specific antibodies. These antibodies can be directed against type 2 transglutaminase enzyme (a-TG2 or endomysial antibodies, EMA) or deamidated gliadin peptides (a-DGP). Years ago, a different commercial kit which combine type 2 transglutaminase and specific gliadin peptides was developed (a-TG2-GL), which can detect antibodies against TG2, against gluten-derived peptides and it has been described that it also recognizes neoepitopes that are generated after the physiological crosslinking between TG2 and gliadin peptides. Regarding genetics, the HLA-DQ2 (DQA1*05 - DQB1*02) and/or HLA-DQ8 (DQA1*03 - DQB1*03:02) haplotypes are the ones considered to confer risk to develop the disease. Duodenal biopsy has an important diagnostic value, although the lesions found in CD are not pathognomonic...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Medicina, leída el 02-06-2016